Latest News

Five Prime Therapeutics Unveils Phase 1 Data

Five Prime Therapeutics Unveils Phase 1 Data

June 5, 2017 at 12:57 pm 0 comments

Five Prime Therapeutics said on Saturday that it presented data from a phase 1 trial of FPA 144 for the treatment of gastric cancer, as well as for cabralizumab in patients with pigmented villonodular synovitis (PVNS) at the American Society of Clinical Oncology Annual Meeting in Chicago. Part 2 of the ongoing phase 1 trial of FPA 144 is evaluatingRead More

XBiotech Shares Higher

XBiotech Shares Higher

June 1, 2017 at 11:38 am 0 comments

XBiotech (XBIT) shares were 9% higher Thursday after the company said its phase 3 study on colorectal cancer patients treated with Hutruo, or MABp1, showed improved clinical outcomes, including reduced disease progression and improved survival for those patients that achieved primary endpoint. The company said that in the study, 82% of all patients that received at least one dose ofRead More

USD-CAD Pulls Back from One-Week High

USD-CAD Pulls Back from One-Week High

May 30, 2017 at 11:37 am 0 comments

USD-CAD has pulled back from the one-week high of 1.3506 posted earlier in the session, currently trading at 1.3473. The pairing had been supported by the reported widening in Canada’s Q1 current account deficit, and West Texas Intermediate crude prices down near $49.00/bbl, though sellers returned above the figure, and the 50-day moving average at 1.3495. Sterling has managed toRead More

Vonage Share Gain

Vonage Share Gain

May 23, 2017 at 3:24 pm 0 comments

Vonage Holdings shares rose more than 7% after William Blair reportedly said the company won a major contract with a top 3 U.S. insurance provider with 100,000 seats that may be the largest Unified Communications as a Service, or UCaaS, deal in history of the channel. William Blair said the company won the deal in January and added roughly 8,000Read More

Albireo Unveils Plans for Phase 3 Clinical Program

Albireo Unveils Plans for Phase 3 Clinical Program

May 18, 2017 at 11:44 am 0 comments

Albireo Pharma, Inc. was out Thursday with key study design details for a planned phase 3 program of lead product candidate, A4250, in patients with progressive familial intrahepatic cholestasis (PFIC) determined following consultations with the U.S. Food and Drug Administration and European Medicines Agency. PFIC is a rare and life-threatening genetic liver disorder for which there are currently no approvedRead More

Coca-Cola Company Signs Deal With Distributor Reyes

Coca-Cola Company Signs Deal With Distributor Reyes

May 16, 2017 at 12:24 pm 0 comments

The Coca-Cola Company has signed a new letter of intent with Reyes Holdings, a food and beverage distribution company, for territory in California and Nevada. The territory includes the metropolitan markets of Los Angeles, San Francisco, San Diego and Las Vegas, Reyes said in a statement. The agreement involves the west operating unit of Coca-Cola Refreshments, which is part ofRead More

Cardiome Pharma Amends Term-Loan Agreement with CRG

Cardiome Pharma Amends Term-Loan Agreement with CRG

May 15, 2017 at 3:19 pm 0 comments

Cardiome Pharma said early Monday it has amended its term-loan agreement with CRG-managed funds originally entered into last June. The amended agreement now provides Cardiome with up to $50 million of available borrowing capacity. The amended loan matures on March 31, 2022. The revised agreement bears interest at 13% per annum. Interest payments may be split, at the company’s option,Read More